Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293–297.
CAS
Google Scholar
Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005:3245.
Gaylis FD, Lin DW, Ignatoff JM, et al.: Prostate cancer in men using testosterone supplementation. J Urol 2005, 174:534–538.
PubMed
Article
CAS
Google Scholar
Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482–492. A major review of the risks of testosterone therapy, with emphasis on PCa.
PubMed
Article
CAS
Google Scholar
Gould DC, Kirby RS: Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:14–18.
PubMed
Article
CAS
Google Scholar
Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299–311. Thoughtful review of the literature, with recommendations regarding monitoring of men receiving testosterone therapy.
PubMed
Google Scholar
Morgentaler A: Testosterone replacement therapy and prostate risks: where's the beef. Can J Urol 2006, 13:S40-S43.
Google Scholar
Barqawi AB, Crawford ED: Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int J Impot Res 2005, 17:462–463.
PubMed
Article
CAS
Google Scholar
Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172:920–922. First paper to suggest that it may be safe to treat men with testosterone after radical prostatectomy.
PubMed
Article
CAS
Google Scholar
Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173:533–536.
PubMed
Article
CAS
Google Scholar
Prout GR, Brewer WR: Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967, 20:1871–1878.
PubMed
Article
Google Scholar
Fowler JE, Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981, 126:372–375.
PubMed
Google Scholar
Sakr WA, Grignon DJ, Crissman JD, et al.: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994, 8:439–443.
PubMed
CAS
Google Scholar
Hsing AW: Hormones and prostate cancer: what's next. Epidemiol Rev 2001, 23:42–58.
PubMed
CAS
Google Scholar
Parsons JK, Carter HB, Platz EA, et al.: Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005, 14:2257–2260.
PubMed
Article
CAS
Google Scholar
Statin P, Lumme S, Tenkanen L, et al.: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004, 108:418–424. Largest of the longitudinal studies, suggesting a relationship of PCa with low testosterone, rather than high testosterone.
Article
CAS
Google Scholar
Chen C, Weiss NS, Stanczyk FZ, et al.: Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003, 12:1410–1416.
PubMed
CAS
Google Scholar
Platz EA, Leitzmann MF, Rifai N, et al.: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005, 14:1262–1269.
PubMed
Article
CAS
Google Scholar
Gann PH, Hennekens CH, Ma J, et al.: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88:1118–1126.
PubMed
Article
CAS
Google Scholar
Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348–2351. Report of testosterone treatment in a group of men at high risk for developing PCa.
PubMed
Article
CAS
Google Scholar
Lefkowitz GK, Taneja SS, Brown J, et al.: Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002, 168:1415–1418.
PubMed
Article
Google Scholar
Morgentaler A, Bruning CO III, DeWolf WC: Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 1996, 276:1904–1906.
PubMed
Article
CAS
Google Scholar
Thompson IM, Pauler DK, Goodman PJ, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level less than or equal to 4 ng per milliliter. N Eng J Med 2004, 350:2239–2246. This paper establishes the modern benchmark for cancer detection rates in men with normal PSA values.
Article
CAS
Google Scholar
Bubley GJ: Is the flare phenomenon clinically significant. Urology 2001, 58(Suppl 2A):5–9.
PubMed
Article
CAS
Google Scholar
Kuhn JM, Billebaud T, Navratil H, et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 1989, 321:413–418.
PubMed
CAS
Article
Google Scholar
Tomera K, Gleason D, Gittelman M, et al.: The gonadotropin-releasing hormone antagonist Abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001, 16:1585–1589.
Google Scholar
Sato N, Akakura K, Isaka S, et al.: Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004, 64:341–345.
PubMed
Article
Google Scholar